GSK To Develop LymphoStat-B With Human Genome Sciences
This article was originally published in The Pink Sheet Daily
Executive Summary
Human monoclonal antibody is in clinical development for the treatment of rheumatoid arthritis and systematic lupus erythematosus. The two firms will share jointly in Phase III and IV development costs, as well as in sales and profits.
You may also be interested in...
Human Genome Sciences Plans to Move LymphoStat-B To Phase III
Firm believes it can proceed with Phase III trials of the lupus agent based on subpopulation findings despite its failure to meet primary endpoints in Phase II.
Human Genome Sciences Plans to Move LymphoStat-B To Phase III
Firm believes it can proceed with Phase III trials of the lupus agent based on subpopulation findings despite its failure to meet primary endpoints in Phase II.
GSK, Human Genome Sciences To Co-Develop Antibody For Cancer Treatment
Human Genome Sciences has completed a Phase II trial of HGS-ETR1 for non-small cell lung cancer, with trials ongoing for non-Hodgkin's lymphoma and colorectal cancer.